Bioverativ Inc. / True North Therapeutics, Inc.

Cold Agglutinin Disease (CAgD)

Disease Overview

Cold agglutinin disease is a rare autoimmune hemolytic anemia in which IgM autoantibodies bind red blood cells at low temperatures, activating the classical complement pathway and triggering chronic hemolysis, profound fatigue, transfusion dependence and elevated thrombosis risk. It accounts for ~15% of autoimmune hemolytic anemias and predominantly affects older adults, with median age of onset around 65-70. Before sutimlimab, no therapies were approved specifically for CAgD — patients were managed with cold avoidance, off-label rituximab and supportive transfusions.

Competitive Landscape

At deal time (May 2017) there were zero FDA-approved therapies for cold agglutinin disease; standard of care was off-label rituximab (with or without bendamustine or fludarabine), corticosteroids and red-blood-cell transfusion, none of which durably controlled hemolysis. True North's TNT009/BIVV009 was a first-in-class humanized anti-C1s monoclonal antibody designed to selectively block the classical complement pathway upstream while leaving the alternative pathway intact — a meaningful differentiator versus Alexion's eculizumab (Soliris), which blocks C5 and is used in PNH/aHUS but not CAgD. The asset earned FDA Breakthrough Designation in May 2017, days before the deal. Jefferies analyst Eun Yang noted Bioverativ would likely take on debt to finance the buyout, framing it as a measured rare-disease portfolio extension beyond hemophilia. Sanofi inherited the asset via its $11.6B Bioverativ acquisition in 2018 and won FDA approval for Enjaymo (sutimlimab-jome) in February 2022 — establishing the first-ever CAgD-specific standard of care. Argenx's complement inhibitors and Roche's crovalimab now represent the next competitive wave.